Collegium Pharmaceutical (COLL) Competitors $39.11 -0.41 (-1.04%) Closing price 04:00 PM EasternExtended Trading$39.12 +0.01 (+0.01%) As of 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock COLL vs. CYTK, VKTX, TGTX, KRYS, ACAD, PCVX, AAPG, ACLX, ADMA, and ZLABShould you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include Cytokinetics (CYTK), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), Vaxcyte (PCVX), Ascentage Pharma Group International (AAPG), Arcellx (ACLX), ADMA Biologics (ADMA), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. Collegium Pharmaceutical vs. Its Competitors Cytokinetics Viking Therapeutics TG Therapeutics Krystal Biotech ACADIA Pharmaceuticals Vaxcyte Ascentage Pharma Group International Arcellx ADMA Biologics Zai Lab Collegium Pharmaceutical (NASDAQ:COLL) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends. Do analysts rate COLL or CYTK? Collegium Pharmaceutical presently has a consensus price target of $42.33, suggesting a potential upside of 8.24%. Cytokinetics has a consensus price target of $71.58, suggesting a potential upside of 86.71%. Given Cytokinetics' higher possible upside, analysts plainly believe Cytokinetics is more favorable than Collegium Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Collegium Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00Cytokinetics 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.93 Is COLL or CYTK more profitable? Collegium Pharmaceutical has a net margin of 5.13% compared to Cytokinetics' net margin of -707.17%. Collegium Pharmaceutical's return on equity of 97.28% beat Cytokinetics' return on equity.Company Net Margins Return on Equity Return on Assets Collegium Pharmaceutical5.13% 97.28% 13.87% Cytokinetics -707.17%N/A -45.52% Which has higher valuation & earnings, COLL or CYTK? Collegium Pharmaceutical has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCollegium Pharmaceutical$631.45M1.95$69.19M$1.0437.61Cytokinetics$18.47M248.39-$589.53M-$5.10-7.52 Which has more volatility and risk, COLL or CYTK? Collegium Pharmaceutical has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Does the media prefer COLL or CYTK? In the previous week, Cytokinetics had 2 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 16 mentions for Cytokinetics and 14 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.91 beat Cytokinetics' score of 0.66 indicating that Collegium Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 9 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCollegium Pharmaceutical beats Cytokinetics on 10 of the 15 factors compared between the two stocks. Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COLL vs. The Competition Export to ExcelMetricCollegium PharmaceuticalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.24B$2.80B$5.82B$9.73BDividend YieldN/A1.66%3.84%4.09%P/E Ratio37.6122.6131.1525.97Price / Sales1.95751.84476.16171.70Price / Cash3.20173.2237.1558.38Price / Book5.315.869.116.39Net Income$69.19M$31.83M$3.26B$265.66M7 Day Performance3.63%1.80%2.11%1.98%1 Month Performance23.61%4.36%5.12%1.33%1 Year Performance8.52%11.44%31.25%21.15% Collegium Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COLLCollegium Pharmaceutical2.235 of 5 stars$39.11-1.0%$42.33+8.2%+10.9%$1.24B$631.45M37.61210News CoverageInsider TradeCYTKCytokinetics3.7434 of 5 stars$38.95+0.7%$71.58+83.8%-32.8%$4.63B$18.47M-7.64250News CoverageVKTXViking Therapeutics4.0243 of 5 stars$42.09+5.1%$86.92+106.5%-60.4%$4.50BN/A-27.5120Trending NewsAnalyst ForecastOptions VolumeTGTXTG Therapeutics4.3543 of 5 stars$27.73-1.2%$46.25+66.8%+14.8%$4.46B$329M74.95290Gap DownKRYSKrystal Biotech4.7511 of 5 stars$146.30-2.6%$210.75+44.1%-27.7%$4.35B$290.52M29.74210Trending NewsAnalyst ForecastACADACADIA Pharmaceuticals3.9708 of 5 stars$25.06-1.1%$28.88+15.2%+55.6%$4.27B$957.80M18.84510Insider TradePCVXVaxcyte2.5279 of 5 stars$32.09-1.9%$136.50+325.4%-60.0%$4.25BN/A-7.81160News CoverageAAPGAscentage Pharma Group InternationalN/A$47.49+5.6%N/AN/A$4.18B$134.35M0.00600News CoverageACLXArcellx2.1985 of 5 stars$71.82-3.1%$114.31+59.2%+7.7%$4.11B$107.94M-21.0080Positive NewsADMAADMA Biologics4.4009 of 5 stars$17.63+3.8%$27.67+56.9%-4.1%$4.05B$474.17M20.50530Positive NewsZLABZai Lab2.8357 of 5 stars$35.69-0.1%$57.22+60.3%+94.2%$3.97B$398.99M-17.501,869News CoverageInsider Trade Related Companies and Tools Related Companies CYTK Competitors VKTX Competitors TGTX Competitors KRYS Competitors ACAD Competitors PCVX Competitors AAPG Competitors ACLX Competitors ADMA Competitors ZLAB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COLL) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access